Gene Expression Signatures

Did you know that there is no current way to measure the levels of hypoxia in tumours?

Due to this, many treatments often don’t work for the patient and it can result in a poor prognosis.

At ManTRa Diagnostics we provide tumour-site-specific gene expression signatures to assess hypoxia. Although specific genetic alterations offer a route to personalised treatments, tumour hypoxia provides a global picture of resistance.

We have developed tumour-site specific gene expression signatures to assess hypoxia. With our technology we can deliver major advances in personalised cancer medicine, with the ultimate goal to allow patients to make more informed choices of their treatment plans.

Our panel detects hypoxia in multiple cancers which means patients will no longer have to suffer unnecessary treatments. We can embed our tests seamlessly within clinical workflows, requiring no additional interventions or biopsies.

Get to know us

Take a look at our blog where we explain more about our assessments, and our recent blog post is about re-thinking commercialisation. We also have more information on our studies and give you a place to learn more about us and meet our team.

If you are interested in discussing our technology and how we can work with you, register your interest via our contact form.